

OncoMethylome Sciences SA

Annual Information Update

This document was prepared by OncoMethylome Sciences SA and provides an overview of the information that has been published or has otherwise been made available to the public by OncoMethylome Sciences SA between January 1 2007 and [February 28, 2008]¹ in one or more member states of the European Economic Area and in third countries in compliance with its obligations under community or national laws and rules dealing with the regulation of securities, company law, issuers of securities and securities markets.

Press Releases

Date	Title	Document location
March 7, 2007	OncoMethylome expands its Amsterdam laboratory	Company website: newsroom
March 27, 2007	OncoMethylome Achieves All 2006 Commercial Goals; 2006 Financial Results Match Expectations	Company website: newsroom
April 20, 2007	OncoMethylome Announces Positive Research Results on its Urine Test for Prostate Cancer	Company website: newsroom
April 27, 2007	OncoMethylome Awarded BioWin Research Grant	Company website: newsroom
May 30, 2007	OncoMethylome's Commercial Partner Veridex Licenses Prostate Cancer Methylation Technology to Laboratory Corporation of America® Holdings	Company website: newsroom
June 12, 2007	OncoMethylome Sciences and EXACT Sciences Announce Commercial Agreements for Colorectal Cancer Screening	Company website: newsroom
September 18, 2007	OncoMethylome Publishes Positive Clinical Trial Results for Urine-based Bladder Cancer Test	Company website: newsroom
September 19, 2007	OncoMethylome's Colorectal Cancer Screening Test Demonstrates High Performance in Clinical Trials	Company website: newsroom
September 20, 2007	OncoMethylome Sciences Reports 2007 Half Year Results and Confirms Successful Product Development	Company website: newsroom
October 16, 2007	OncoMethylome Sciences Engaged in Private Share Offering	Company website: newsroom
October 16, 2007	OncoMethylome Sciences Successfully Completes Private Share Offering Raising €10.6 million	Company website: newsroom
November 19, 2007	OncoMethylome's Biomarkers Demonstrate Good Performance in Detecting Colorectal Cancer in Blood	Company website: newsroom
November 26, 2007	OncoMethylome Sciences to Collaborate with GlaxoSmithKline Biologicals for Personalized Cancer Treatment	Company website: newsroom
December 17, 2007	OncoMethylome Sciences to Profile DNA for Abbott Oncology Compounds	Company website: newsroom
January 14, 2008	OncoMethylome Sciences S.A. Licenses Several Key Technologies from Epigenomics AG	Company website: newsroom
January 30, 2008	OncoMethylome Sciences SA to Initiate a Large Colorectal Cancer Clinical Trial and Acquire Minority Interest in Signature Diagnostics AG	Company website: newsroom

¹ In accordance with circular note FMI/2003-02 of the Belgian Banking, Finance and Insurance Commission, this overview was closed as per February 28, 2008, being the date on which the board of directors of OncoMethylome Sciences SA established the annual accounts for financial year 2007.

Other

Date	Document	Document location
April 18, 2007, October 25, 2007	Updated articles of association	Company website: investors/corporate governance
April 19, 2007, June 27, 2007, October 26, 2007, December 31, 2008	Updated denominator document	Company website: investors/share
April 19, 2007, October 26, 2007	Updated history of share capital	Company website: investors/share
May 18, 2007	OncoMethylome Sciences SA - Excerpt from the board meeting held on April 18, 2007 relating to the issuance of warrants	Belgian official gazette (07071602)
May 24, 2007	OncoMethylome Sciences SA - Excerpt from the notary deed dated April 18, 2007 relating to the confirmation of the exercise of warrants, the issuance of shares and corresponding capital increase	Belgian official gazette (07073858)
May 31, 2007	OncoMethylome BVBA - Excerpt from incorporation deed dated May 25, 2007	Belgian official gazette (07300321)
June 20, 2007	OncoMethylome Sciences SA - Excerpt from the EGSM of May 25, 2007 relating to the issuance of warrants	Belgian official gazette (07087296)
June 27, 2007	OncoMethylome Sciences SA - Confirmation of the filing of the FY07 annual accounts	Belgian official gazette (07099278)
July 9, 2007	OncoMethylome Sciences SA - Excerpt from the AGSM of May 25, 2007 relating to re-election of the directors	Belgian official gazette (07098833)
July 18, 2007	OncoMethylome BVBA - Excerpt from capital increase deed dated June 26 2007	Belgian official gazette (07106269)
November 6, 2007	OncoMethylome Sciences SA - Excerpt from the board meeting relating to the capital increase in the framework of the authorized capital (private placement) of October 15, 2007	Belgian official gazette (07160151)
November 6, 2007	OncoMethylome Sciences SA - Excerpt confirmation of the capital increase in the framework of the authorized capital (private placement) of October 19, 2007	Belgian official gazette (07160150)
November 9, 2007	OncoMethylome Sciences SA - Excerpt from the notary deed dated October 25, 2007 relating to the confirmation of the exercise of warrants, the issuance of shares and corresponding capital increase	Belgian official gazette (07162369)
February 7, 2008	OncoMethylome Sciences SA - Excerpt relating to the change of permanent representatives ING and Sogam	Belgian official gazette (08021616)

Notes

This overview was prepared and is made available pursuant to article 66 of the Act of June 16, 2006 regarding the public offering of financial instruments and the admission to listing of financial instruments on a regulated market, implementing the provisions of article 10 of the Prospectus Directive (Directive 2003/71/EC of the European Parliament and of the Council of November 4, 2003 on the prospectus to be published when securities are offered to the public or admitted to trading and amending Directive 2001/34/EC) into Belgian law. The overview has not been prepared and is not made available for any other purposes. The company, nor any other person, assumes any responsibility, or gives any express or implied warranty, regarding the completeness or accuracy of the information included in this overview.

The information referred to in this overview may no longer be up to date at the date hereof and may hence no longer be accurate. Other, more recent information may have been published after the date on which this overview has been closed.

This document does not constitute an offer to sell or an invitation to submit an offer to purchase shares or other securities of OncoMethylome Sciences SA. When considering investing in OncoMethylome Sciences SA, potential investors should rely on their own judgment and investigations regarding the company and the modalities of such shares and securities.

About OncoMethylome Sciences SA

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation's BioScience Division, and EXACT Sciences Corp. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).